Lysosome-Targeted Bifunctional Therapeutics Induce Autodynamic Cancer Therapy

Autodynamic cancer therapy possesses tremendous potential for enhancing therapeutic efficacy by initiating the treatment process autonomously within targeted cells. However, challenges related to biocompatibility and targeted delivery have hindered its clinical translation owing to the induction of adverse effects and cytotoxicity in healthy cells. In this study, a novel approach for auto-initiated dynamic therapy by conjugating zwitterionic near-infrared fluorophores to a cell-penetrating peptide is proposed. This enables efficient cellular uptake and specific targeting of therapy to desired cells while avoiding off-target uptake. The zwitterionic bioconjugate causes cancer-specific toxicity following its internalization into the targeted cells, triggered by specific intracellular conditions in lysosomes. This innovative approach enables selective targeting of lysosomes in malignant cells while minimizing cytotoxic effects on normal cells. By targeting lysosomes, the method overcomes inherent risks and side effects associated with conventional cancer treatments, offering a selective and effective approach to cancer therapy. The study focuses on a novel auto-initiated cancer therapy that employs zwitterionic near-IR fluorophores attached to cell-penetrating peptides for accurate targeting. This method guarantees efficient cellular absorption and precise targeting, leading to cancer-specific toxicity within the lysosomes of malignant cells. This selective targeting improves the effectiveness of cancer treatments and reduces side effects, making it a highly desirable approach in oncology. image